Evaluating visual rehabilitation's effects on anxiety and depression in patients with AMD
Evaluation of the Impact of Visual Rehabilitation on Anxiety and Depression Severity of Visually Impaired Patients with Advanced Age Related Macular Degeneration
This study is testing whether a visual rehabilitation program can help reduce anxiety and depression in people with advanced age-related macular degeneration.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 22 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | Fondazione G.B. Bietti, IRCCS Academic / other |
| Locations | 1 site (Rome, Italy) |
| Trial ID | NCT06906003 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the impact of a visual rehabilitation program on anxiety and depression levels in visually impaired patients suffering from advanced age-related macular degeneration (AMD). Participants will undergo a series of assessments, including ophthalmological examinations and questionnaires measuring anxiety and depression. The study involves three visits: an initial screening, a 60-day rehabilitation program with group meetings, and a final evaluation to measure outcomes. The research is conducted at two locations in Rome, Italy.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 55 and older with moderate to severe visual impairment due to advanced non-exudative AMD.
Not a fit: Patients with visual impairment from other ocular diseases or those with mild visual impairment or total blindness may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the mental health and quality of life for visually impaired patients with AMD.
How similar studies have performed: Other studies have shown positive outcomes in visual rehabilitation programs for similar patient populations, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects ≥ 55 years 2. Moderate and severe visual impairment (BCVA ≥1/10 and ≤2/10) 3. Diagnosis of advanced non-exudative age-related macular degeneration (AMD) 4. Informed consent freely granted and acquired before the start of the study 5. Ability to understand and willingness to follow the study instructions and procedures Exclusion Criteria: 1. Visual impairment due to other ocular diseases 2. Mild visual impairment or partial or total blindness 3. Exudative age-related macular degeneration undergoing intravitreal drug treatment
Where this trial is running
Rome, Italy
- IRCCS Fondazione G.B.Bietti — Rome, Italy, Italy (Recruiting)
Study contacts
- Study coordinator: Eliana Costanzo, MD
- Email: eliana.costanzo@fondazionebietti.it
- Phone: +390684009442
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.